WASHINGTON — For years, the most talked-about weight-loss drugs in America came with a price tag that put them out of reach for many of the people who could use them, including older Americans on Medicare. That is about to change. The Centers for Medicare & Medicaid Services (CMS), the federal agency that runs Medicare, said ahead of a July 1 launch that eligible members of Medicare drug plans will be able to get certain GLP-1 medications for a flat $50 a month.

The program is called the Medicare GLP-1 Bridge, and it runs from July 1, 2026, through the end of 2027.

GLP-1s are the class of drugs that started as diabetes treatments and are now widely used to manage obesity and related conditions. The best-known brands are Wegovy, made by Novo Nordisk, and Zepbound, made by Eli Lilly, along with a newer Eli Lilly pill called Foundayo. At full list price, these drugs can run well over $1,000 a month, which is why cost has been the single biggest barrier for most patients.

Under the Bridge, the $50 charge is the patient’s total out-of-pocket cost for a monthly supply. CMS said that starting July 1, all versions of Wegovy, all versions of the Foundayo pill, and the KwikPen version of Zepbound will be available through the program. A few forms of Zepbound, including single-dose vials and pens, will not be covered.

There is a reason the government had to build a special workaround. By law, Medicare’s Part D drug plans are barred from covering medicines used purely for weight loss. Making that coverage permanent would take an act of Congress. To get around the limit for now, CMS is using its authority to run temporary demonstration programs — which is why the Bridge is time-limited and carries that name.

Not everyone qualifies. A person must be enrolled in a Medicare Part D drug plan, and eligibility is tied to body weight: a body mass index of 35 or higher, or 27 or higher combined with other health conditions. CMS said beneficiaries do not need to sign up or opt in; instead, a doctor submits a prior-authorization request and prescription.

For Eli Lilly and Novo Nordisk, the move opens a large new door. Medicare covers tens of millions of seniors, and even limited access to that group adds a major new wave of demand for two companies already racing each other for the obesity market. It is also a significant new cost for taxpayers, which is part of why the government capped the program’s length rather than making it open-ended.

The Bridge is also part of a wider push to bring obesity-drug prices down. Under separate deals with the Trump administration, Eli Lilly and Novo Nordisk agreed to cut prices, and their new oral pills start around $149 a month for people paying cash.

There is a catch worth understanding. After 2027, coverage is meant to shift to a separate, longer-term program that individual drug plans can choose to join. That follow-on plan has been delayed and remains uncertain, which means seniors who start getting their medication through the Bridge could face changes to their coverage down the road.

For now, the bottom line is simple. Beginning July 1, a class of drugs that has reshaped both the health-care and food industries becomes affordable for millions of older Americans for the first time — at least for the next year and a half.

JBizNews Desk — Washington

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited